neutral
Recently
Novo Nordisk outlines pricing approach for weight-loss drug in India
Novo Nordisk said Ozempic pricing in India will reflect a balance between scientific innovation, affordability, and competitive dynamics, as demand for obesity and diabetes treatments continues to rise across key markets.
Novo Nordisk’s India leadership said the company aims to balance scientific innovation with competitive pricing as it expands access to Ozempic in the country. The management highlighted that pricing decisions are shaped by research investment, patient affordability, and long-term market sustainability. As demand for obesity and diabetes treatments grows, the company plans to rely on clinical evidence and manufacturing scale while remaining responsive to competitive pressures and evolving healthcare dynamics in India.